Stephen B. Shrewsbury
Executive VP, Development & CMO
Fortuna Fix
USA
Biography
Dr Stephen Shrewsbury is currently Executive Vice President of Development and Chief Medical Officer at Fortuna Fix, leading their novel cellular technology into multiple clinical programs focused on Regenerative Medicine, several of which are rare diseases. A UK trained physician, Dr Shrewsbury first joined Glaxo 23 years ago. He moved to lead inhaled antibiotic programs at Chiron Corporation (in Cystic Fibrosis and other rare diseases) before becoming CMO sequentially to MAP Pharmaceuticals, Adamas Pharmaceuticals, AVI BioPharma (now Sarepta Therapeutics – where he opened their first IND for eteplirsen in Duchenne Muscular Dystrophy and planned their oligomer programs against Ebola and Marburg Hemorrhagic Fevers) and Aquinox Pharmaceuticals. He has now moved from Drugs (and Devices) and Oligonucleotides to lead programs with directly reprogrammed precursor cells and tackle many rare, and currently untreatable, diseases with great social and healthcare impact. He is author of Defy Your DNA and over 70 scientific papers, holds several patents and contributed to many awarded grants – mostly for work on rare diseases.
Research Interest
.